Lexeo Therapeutics, Inc Common Stock
Price & Volume
Stats
See more52W Range | $3.99-$10.99 |
Market Cap | $344.5M |
Shares Short | 20M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$66.6M |
Diluted EPS | -$0.88 |
News
See moreYahoo Finance • last month
Lexeo's LX2020 Secures FDA RMAT Tag For PKP2-Associated Arrhythmogenic Cardiomyopathy
Yahoo Finance • last month
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Yahoo Finance • 2 months ago
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple
Yahoo Finance • 3 months ago
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
About
CEO | Mr. R. Nolan Townsend M.B.A. |
CFO | Mr. Louis Tamayo |
Address | 345 Park Avenue South, New York, NY, United States, 10010 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 63 |